We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Biogen Isn’t Letting Numbers Rain on Its Tofersen Parade
Biogen Isn’t Letting Numbers Rain on Its Tofersen Parade
Tofersen, Biogen’s potential blockbuster for amyotrophic lateral sclerosis (ALS) caused by mutations of the SOD1 gene, has missed its primary endpoint of improved function in a highly anticipated trial.